HomeCompareCTHRQ vs JNJ

CTHRQ vs JNJ: Dividend Comparison 2026

CTHRQ yields 15209.13% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CTHRQ wins by $3473564864705308672.00M in total portfolio value
10 years
CTHRQ
CTHRQ
● Live price
15209.13%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3473564864705308672.00M
Annual income
$3,429,211,375,591,879,600,000,000.00
Full CTHRQ calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CTHRQ vs JNJ

📍 CTHRQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTHRQJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTHRQ + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTHRQ pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTHRQ
Annual income on $10K today (after 15% tax)
$1,292,775.67/yr
After 10yr DRIP, annual income (after tax)
$2,914,829,669,253,097,500,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, CTHRQ beats the other by $2,914,829,669,253,097,500,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTHRQ + JNJ for your $10,000?

CTHRQ: 50%JNJ: 50%
100% JNJ50/50100% CTHRQ
Portfolio after 10yr
$1736782432352654336.00M
Annual income
$1,714,605,687,795,939,800,000,000.00/yr
Blended yield
98.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CTHRQ
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-3.9
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTHRQ buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTHRQJNJ
Forward yield15209.13%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$3473564864705308672.00M$30.3K
Annual income after 10y$3,429,211,375,591,879,600,000,000.00$4,689.40
Total dividends collected$3470630504683258880.00M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CTHRQ vs JNJ ($10,000, DRIP)

YearCTHRQ PortfolioCTHRQ Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$1,531,613$1,520,912.55$10,592$272.30+$1.52MCTHRQ
2$219,344,315$217,705,489.86$11,289$357.73+$219.33MCTHRQ
3$29,372,921,960$29,138,223,543.14$12,123$472.89+$29372.91MCTHRQ
4$3,678,129,229,453$3,646,700,202,954.87$13,141$629.86+$3678129.22MCTHRQ
5$430,707,792,715,276$426,772,194,439,761.75$14,408$846.81+$430707792.70MCTHRQ
6$47,166,363,589,446,140$46,705,506,251,240,810.00$16,021$1,151.60+$47166363589.43MCTHRQ
7$4,830,534,868,893,136,000$4,780,066,859,852,428,000.00$18,122$1,588.22+$4830534868893.12MCTHRQ
8$462,691,766,266,782,700,000$457,523,093,957,067,000,000.00$20,930$2,228.20+$462691766266782.69MCTHRQ
9$41,451,858,984,513,220,000,000$40,956,778,794,607,770,000,000.00$24,792$3,191.91+$41451858984513224.00MCTHRQ
10$3,473,564,864,705,309,000,000,000$3,429,211,375,591,879,600,000,000.00$30,274$4,689.40+$3473564864705308672.00MCTHRQ

CTHRQ vs JNJ: Complete Analysis 2026

CTHRQStock

Charles & Colvard, Ltd. operates as a fine jewelry company in the United States and internationally. It operates through two segments: Online Channels and Traditional. The company manufactures, markets, and distributes moissanite jewels and finished moissanite jewelry under the Charles & Colvard Created Moissanite brand; and premium moissanite gemstones under the Forever One brand name. It also markets and distributes lab grown diamonds and finished jewelry with lab grown diamonds under the Caydia brand. It sells its products at wholesale prices to distributors, manufacturers, retailers, and designers; and to end-consumers at retail prices through charlesandcolvard.com and moissaniteoutlet.com, third-party online marketplaces, drop-ship, and other e-commerce outlets, as well as through Charles & Colvard Signature Showroom and charlesandcolvarddirect.com for wholesale and retail customers. Charles & Colvard, Ltd. was incorporated in 1995 and is headquartered in Morrisville, North Carolina. On March 2, 2026, Charles & Colvard, Ltd. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Full CTHRQ Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CTHRQ vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTHRQ vs SCHDCTHRQ vs JEPICTHRQ vs OCTHRQ vs KOCTHRQ vs MAINCTHRQ vs ABBVCTHRQ vs MRKCTHRQ vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.